IPO
Explore our secure online trading, IPO bidding, mutual fund investments, and depository services, all designed to provide seamless transactions, expert insights, and real-time market access for smart investing
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd
Registered Office : Plot No. 170-172 Chandramouli,Industrial Est.Mohol Bazarpeth,Solapur Maharashtra 413213 Phone : 91-2189-234456/234246
Fax :
Email : complianceofficer@glenmarklifesciences.com
Website : www.glenmarklifesciences.com
Initial public offer of 21,022,222 equity shares of face value of Rs. 2 each ("equity shares") of Glenmark Life Sciences Limited ("Company" or "Issuer") for cash at a price of Rs. 720 per equity share (including a share premium of Rs. 718 per equity share) aggregating to Rs. 1513.60 crores (the "offer") comprising a fresh issue of 14,722,222 equity shares aggregating to Rs. 1060 crores (the "fresh issue") and an offer for sale of up to 6,300,000 equity shares by Glenmark Pharmaceuticals Limited ("Promoter Selling Shareholder") and such equity shares, The "offered shares") aggregating to Rs. 453.60 crores (The "offer for sale"). The offer shall constitute 17.16% of the post-offer paid-up equity share capital of the company. The face value of equity shares is Rs. 2 each. Offer Price : Rs. 720 per Equity Share of face value of Rs. 2 each. Anchor Investor offer price: Rs. 720 per Equity share. The Offer Price is 360 times the face value.
Opens On
Closes On
27-Jul-2021
29-Jul-2021
Application
Allotment
720.00
0.00
Minimum Application for shares in Nos : 20.0 Further Multiples of : 20.0
₹Cr
Lead Managers to the Issue
Project Cost (₹.Cr)
Project Financed through Current Offer (₹.Cr)
Post Issue Equity Share Capital (₹.Cr)
Issue Price (₹.Cr)
1,060.00
1,513.60
24.51
720.00
BOB Capital Markets Ltd
BofA Securities India Ltd
DAM Capital Advisors Ltd
Goldman Sachs (India) Securities Pvt Ltd
Kotak Mahindra Capital Company Ltd
SBI Capital Markets Ltd
- Payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company pursuant to the Business Purchase agreement
- Funding capital expenditure requirements
- General corporate purposes
- Glenmark Pharmaceuticals Ltd
- BSE
- NSE
- KFin Techologies Ltd